• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 6:34:17 AM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    omcl-20250506
    0000926326false00009263262025-05-062025-05-06


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D. C.  20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported):  May 6, 2025

    OMNICELL, INC.
    (Exact name of registrant as specified in its charter)

    Delaware000-3304394-3166458
    (State or other jurisdiction of
    incorporation)
    (Commission File Number)(IRS Employer Identification Number)

    4220 North Freeway
    Fort Worth, TX 76137
    (Address of principal executive offices, including zip code)

    (877) 415-9990
    (Registrant’s telephone number, including area code)


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading SymbolName of each exchange on which registered
    Common Stock, $0.001 par valueOMCLNASDAQ Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02 Results of Operations and Financial Condition.
    On May 6, 2025, Omnicell, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025 and updating its guidance for the full year 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
    The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits.
    Exhibit NumberExhibit Description
    99.1
    Press release entitled “Omnicell Announces First Quarter 2025 Results” dated May 6, 2025
    104Cover Page Interactive Data File (embedded within the inline XBRL document)




    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

    OMNICELL, INC.
    Date: May 6, 2025
    /s/ Nchacha E. Etta
    Nchacha E. Etta
    Executive Vice President and Chief Financial Officer




    Get the next $OMCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings